StocktoriaNexentis Technologies Inc. NXTS
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
3/9
Piotroski F — financial health
-2.48
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | — | $210,000 | $263,000 | $394,004 | $438,141 |
| Gross profit | — | $45,000 | $208,000 | $235,691 | $302,198 |
| Operating income | -$4.2M | -$3.3M | -$7.6M | -$5.8M | -$4.7M |
| Net income | -$4.0M | -$5.2M | -$6.5M | -$5.7M | -$4.8M |
| Operating cash flow | -$3.8M | -$3.4M | -$3.2M | -$5.1M | -$4.1M |
| Free cash flow | -$3.8M | — | — | -$5.1M | -$4.2M |
| Total assets | $20.4M | $5.5M | $7.2M | $6.5M | $7.6M |
| Total liabilities | $4.7M | $892,000 | $786,000 | $754,872 | $1.2M |
| Shareholders' equity | $16.0M | $4.6M | $6.5M | $5.7M | $6.4M |
| Ratios | |||||
| Gross margin | — | 21.4% | 79.1% | 59.8% | 69.0% |
| Operating margin | — | -1563.3% | -2881.4% | -1477.1% | -1073.5% |
| Net margin | — | -2472.9% | -2479.8% | -1456.7% | -1100.2% |
| FCF margin | — | — | — | -1306.8% | -954.3% |
| Return on assets | -19.6% | -95.0% | -90.0% | -88.4% | -63.5% |
| Return on equity | -25.0% | -113.6% | -101.0% | -100.0% | -75.2% |
| Debt / equity | — | — | — | — | 0.00× |
| Current ratio | 4.19 | 3.87 | 7.02 | 8.77 | 7.76 |
| Revenue growth | — | -20.2% | -33.2% | -10.1% | 88.6% |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -2.48 (distress)
- Working capital / assets 0.224
- Retained earnings / assets -1.89
- EBIT / assets -0.207
- Equity / liabilities 3.425
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001789192 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.